M A Masri

Summary

Affiliation: Rizk Hospital
Country: Lebanon

Publications

  1. ncbi Technical limitations of immunosuppressive drug therapy blood level monitoring
    M A Masri
    Transplant Unit, Rizk Hospital, Beirut, Lebanon
    Transplant Proc 35:2755-6. 2003
  2. ncbi Bioavailability versus bioequivalence: the cyclosporine model
    Marwan A Masri
    Transplant Unit of Rizk Hospital, Beirut, Lebanon
    Exp Clin Transplant 1:119-24. 2003
  3. ncbi Middle East Society for Organ Transplantation (MESOT) Transplant Registry
    Marwan A Masri
    Rizk Hospital, Lebanon
    Exp Clin Transplant 2:217-20. 2004
  4. ncbi The role of generics in transplantation
    M A Masri
    Rizk Hospital, Lebanon
    Transplant Proc 35:2745-7. 2003
  5. ncbi The mosaic of immunosuppressive drugs
    Marwan A Masri
    Rizk Hospital, P O Box 11 3288, Beirut, Lebanon
    Mol Immunol 39:1073-7. 2003
  6. ncbi Cyclosporine blood level monitoring. Cross-reactivity of anti-cyclosporine A monoclonal with its sulphate metabolite: an in vitro study
    Marwan Masri
    Rizk Hospital, P O Box 11 2388, Beirut, Lebanon
    Mol Immunol 39:1059-60. 2003
  7. ncbi An assay for the determination of sirolimus levels in the lymphocyte of transplant patients
    M Masri
    Transmedical Research Institute, Beirut, Lebanon
    Transplant Proc 39:1204-6. 2007
  8. ncbi Switchability of neoral and equoral according to Food and Drug Administration rules and regulations
    M A Masri
    Rizk Hospital, Ankara Turkey
    Transplant Proc 37:2988-93. 2005
  9. ncbi Cyclosporine lymphocyte maximum level monitoring in de novo kidney transplant patients: a prospective study
    A G Barbari
    Nephrology and Transplantation Unit, Rizk Hospital, Beirut, Lebanon
    Exp Clin Transplant 4:400-5. 2006
  10. ncbi Mycophenolic acid plasma trough level: correlation with clinical outcome
    A Barbari
    Nephrology and Transplantation Unit, Rizk Hospital, Ashrafieh, Beirut, Lebanon
    Exp Clin Transplant 3:355-60. 2005

Collaborators

Detail Information

Publications17

  1. ncbi Technical limitations of immunosuppressive drug therapy blood level monitoring
    M A Masri
    Transplant Unit, Rizk Hospital, Beirut, Lebanon
    Transplant Proc 35:2755-6. 2003
  2. ncbi Bioavailability versus bioequivalence: the cyclosporine model
    Marwan A Masri
    Transplant Unit of Rizk Hospital, Beirut, Lebanon
    Exp Clin Transplant 1:119-24. 2003
    ..4 and a within-run CV is 3.1. For this study, blood and lymphocyte drug levels in transplant patients were determined and correlated with graft function and clinical events (biopsy-proven rejection and/ or toxicity)...
  3. ncbi Middle East Society for Organ Transplantation (MESOT) Transplant Registry
    Marwan A Masri
    Rizk Hospital, Lebanon
    Exp Clin Transplant 2:217-20. 2004
    ..Costs for transplantation and immunosuppressive therapy are either totally or heavily supported by governmental agencies...
  4. ncbi The role of generics in transplantation
    M A Masri
    Rizk Hospital, Lebanon
    Transplant Proc 35:2745-7. 2003
  5. ncbi The mosaic of immunosuppressive drugs
    Marwan A Masri
    Rizk Hospital, P O Box 11 3288, Beirut, Lebanon
    Mol Immunol 39:1073-7. 2003
    ....
  6. ncbi Cyclosporine blood level monitoring. Cross-reactivity of anti-cyclosporine A monoclonal with its sulphate metabolite: an in vitro study
    Marwan Masri
    Rizk Hospital, P O Box 11 2388, Beirut, Lebanon
    Mol Immunol 39:1059-60. 2003
    ..The results with other CYA monoclonal was also similar. These results suggest that blood level monitoring of CYA many not be accurate as all the monoclonal antibodies currently used cross react with the metabolites...
  7. ncbi An assay for the determination of sirolimus levels in the lymphocyte of transplant patients
    M Masri
    Transmedical Research Institute, Beirut, Lebanon
    Transplant Proc 39:1204-6. 2007
    ..6.06). The higher the concentration of the drug the lower the lymphocyte counts. The assay is sensitive to within 0.45 pg/cell, reproducible with a coefficient of variance (CV) of 6.4% within assay and 7.5% for intraassay...
  8. ncbi Switchability of neoral and equoral according to Food and Drug Administration rules and regulations
    M A Masri
    Rizk Hospital, Ankara Turkey
    Transplant Proc 37:2988-93. 2005
    ....
  9. ncbi Cyclosporine lymphocyte maximum level monitoring in de novo kidney transplant patients: a prospective study
    A G Barbari
    Nephrology and Transplantation Unit, Rizk Hospital, Beirut, Lebanon
    Exp Clin Transplant 4:400-5. 2006
    ..To determine prospectively the temporal variations of cyclosporine-A lymphocyte maximum level, whole blood maximum concentration, and total lymphocyte count in patients with de novo kidney transplantation...
  10. ncbi Mycophenolic acid plasma trough level: correlation with clinical outcome
    A Barbari
    Nephrology and Transplantation Unit, Rizk Hospital, Ashrafieh, Beirut, Lebanon
    Exp Clin Transplant 3:355-60. 2005
    ..Assess the relationship between clinical diagnosis, state of immunosuppression, mycophenolic acid (MPA) plasma trough levels (MPACmin), and mycophenolate mofetil (MMF) dosage in renal transplant recipients...
  11. ncbi The role of generics in transplantation: TM-MMF versus Cellcept in healthy volunteers
    M A Masri
    Rizk Hospital, Beirut, Lebanon
    Transplant Proc 36:84-5. 2004
    ..Both products showed similar bioavailability. The LSM were within the limits for FDA approval (80 to 125), suggesting that the two products are equivalent and switchable...
  12. ncbi Bioavailability of a new generic formulation of mycophenolate mofetil MMF 500 versus CellCept in healthy adult volunteers
    M A Masri
    TransMedical Drug Evaluation Center, Beirut, Lebanon
    Transplant Proc 39:1233-6. 2007
    ..6%, and 105%, respectively, which is within the Food and Drug Administration (FDA)-assigned range for immunosuppressive drugs (90% to 111%). These results indicated that the products are equivalent and switchable according to FDA rulings...
  13. ncbi Cytokine gene polymorphism in a Lebanese transplant population and its impact on graft acceptance: a single-center pilot study
    M A Masri
    Transplant and Nephrology Unit, Rizk Hospital, Beirut, Lebanon
    Transplant Proc 35:251-2. 2003
  14. ncbi Nephron mass in kidney transplantation
    A Barbari
    Nephrology and Transplantation Unit, Rizk Hospital, Beirut, Lebanon
    Transplant Proc 34:2401-2. 2002
  15. ncbi Pre- and posttransplant immunologic monitoring: why, when, and how?
    M A Masri
    Rizk Hospital, Beirut, Lebanon
    Transplant Proc 34:2482-4. 2002
  16. ncbi Cyclosporine lymphocyte maximum level: a new alternative for cyclosporine monitoring in kidney transplantation
    Antoine G Barbari
    Nephrology and Transplantation Unit, Rizk Hospital, Beirut, Lebanon
    Exp Clin Transplant 3:293-300. 2005
    ..To determine the relationship between clinical outcome, lymphocyte count (LC), and cyclosporine (CsA) lymphocyte maximum level (LT(m)L) in kidney transplant recipients...
  17. ncbi Pharmacokinetic conversion study of a new cyclosporine formulation in stable adult renal transplant recipients
    Frantisek Perlík
    Institute of Pharmacology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149:309-13. 2005
    ..h, respectively. The 90 % confidence intervals of C(max) and AUCtau were within 80- 125 % interval of the mean values. The results suggest that Equoral capsules can be used as an alternative treatment to Neoral capsules in CyA regimen...